Identification of CD8+ T cell epitopes within lytic antigens of human herpes virus 8

E Ribechini, C Fortini, M Marastoni… - The Journal of …, 2006 - journals.aai.org
E Ribechini, C Fortini, M Marastoni, S Traniello, S Spisani, P Monini, R Gavioli
The Journal of Immunology, 2006journals.aai.org
Abstract The human herpesvirus 8 (HHV-8) is a γ herpesvirus with oncogenic potential
which establishes a chronic infection that is normally controlled by the immune system of
healthy individuals. In particular, CTL responses seem to play a key role in control of the
infection. In this study, we characterized epitope-specific CTL responses in healthy HHV-8-
seropositive individuals against four HHV-8 lytic Ags: open reading frames (ORF) 26, 70, K3,
and K5. We found that the majority of subjects responded to at least one HHV-8 lytic Ag …
Abstract
The human herpesvirus 8 (HHV-8) is a γ herpesvirus with oncogenic potential which establishes a chronic infection that is normally controlled by the immune system of healthy individuals. In particular, CTL responses seem to play a key role in control of the infection. In this study, we characterized epitope-specific CTL responses in healthy HHV-8-seropositive individuals against four HHV-8 lytic Ags: open reading frames (ORF) 26, 70, K3, and K5. We found that the majority of subjects responded to at least one HHV-8 lytic Ag-derived epitope, and some of these epitopes represented dominant targets, suggesting that they could be relevant targets of CTL-mediated immunity in vivo, and may be involved in host control of HHV-8. Specifically, we identified three CTL epitopes from ORF 26, which are presented by HLA-A2, six CTL epitopes from ORF 70 presented by HLA-A2 (three epitopes),-A24 (two epitopes), and-B7 (one epitope), three CTL epitopes from ORF K3 presented by HLA-A2 (two epitopes) and-B7 (one epitope), and one HLA-A2 presented epitope derived from ORF K5. The identified epitopes may be regarded as useful tools for understanding the role of CTL responses to lytic Ags in individuals affected by HHV-8-associated disorders, and for the development of immunotherapies for the treatment/prevention of HHV-8-associated malignancies.
journals.aai.org